ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Robbins Geller Rudman & Dowd LLP Announce Proposed Settlement in the Puma Biotechnology, Inc. Securities Settlement

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc. Securities Settlement:

UNITED STATES DISTRICT COURT

CENTRAL DISTRICT OF CALIFORNIA

SOUTHERN DIVISION

HSINGCHING HSU, INDIVIDUALLY AND

)

Case No. 8:15-cv-00865-AG-SHK

ON BEHALF OF ALL OTHERS

)

 

SIMILARLY SITUATED,

)

 

PLAINTIFF,

)

CLASS ACTION

VS.

)

PUMA BIOTECHNOLOGY, INC., ET AL.,

)

DEFENDANTS.

)

Notice of class action settlement

You are hereby notified, pursuant to Rule 23 of the Federal Rules of Civil Procedure and Order of the United States District Court for the Central District of California, that a Settlement has been proposed in the above-captioned action. You can identify if your claim has been validated and the amount of your damages and prejudgment interest at the website listed below. If you have submitted a validated claim, you do not need to do anything in order to receive your share of the settlement.

The parties have agreed to a proposed settlement of the litigation for $54,248,374.00 (the “Settlement Amount”). The Settlement Amount represents the complete amount of claimed damages and prejudgment interest due to validated claims under the jury verdict. If approved, the settlement will finally resolve all claims in the litigation. Based on your previously submitted claim form and the damages calculations performed by the Claims Administrator, you will receive 100% of your damages and prejudgment interest less: (i) your pro rata share of any Court-awarded attorneys’ fees and litigation expenses and any Court award to the Lead Plaintiff; (ii) settlement administration expenses; and (iii) taxes and tax expenses. Class Counsel have prosecuted this case on a wholly contingent basis and will apply to the Court for: (i) an award of attorneys’ fees of 25% of the Settlement Amount; (ii) payment of litigation expenses paid or incurred by Class Counsel in an amount not to exceed $3,100,000; and (iii) an award to Lead Plaintiff in an amount not to exceed $100,000, pursuant to 15 U.S.C. §78u-4(a)(4). The requested attorneys’ fees and expenses represent approximately $1.33 per share.

You have the right to object to the application for Class Counsel’s fees or expenses and/or the application for the Lead Plaintiff award. Any objection is due by March 21, 2022. For more information on filing an objection, please go to the website listed below.

A Settlement Hearing is scheduled for April 11, 2022, at 8:00 a.m., at the United States District Court for the Central District of California, Ronald Reagan Federal Building and U.S. Courthouse, 411 West Fourth Street, Courtroom 9d, Santa Ana, CA. 92701 for the purpose of determining, among other things, (i) whether the Settlement and Plan of Allocation are fair, reasonable, and adequate, and should be approved; and (ii) to consider the application of Lead Counsel for an award of attorneys’ fees and expenses, and any application for an award to Lead Plaintiff.

If you have any questions, you can contact Class Counsel, Tor Gronborg, at 1-619-231-1058 or visit:

www.pumabiosecuritieslitigation.com

Contacts

Tor Gronborg, 1-619-231-1058

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.